Clinical Trial Update: Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating first-line taxane/carboplatin with or without cetuximab in advanced/metastatic non-small cell lung cancer; results were posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Cetuximab (cetuximab)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Non-Small-Cell Lung Carcinoma | Phase 3 | Status: COMPLETED | Results posted: 2010-10-05